Risk of Malnutrition in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease Treated With Nintedanib in the Randomized, Placebo-Controlled SENSCIS Trial.

ABSTRACT:

Objective

To assess adverse events (AEs) in relation to baseline body mass index (BMI) and the risk of malnutrition in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) treated with nintedanib.

Methods

Among patients with SSc-ILD randomized to receive nintedanib or placebo in the SENSCIS trial, we assessed AEs in subgroups by baseline BMI ≤20 kg/m² and BMI >20 kg/m² , and the risk of malnutrition using a modified version of the Malnutrition Universal Screening Tool (MUST), over 52 weeks.

Results

The AE profile of nintedanib was similar between subgroups with a baseline BMI ≤20 kg/m² (n = 61) and a baseline BMI >20 kg/m² (n = 515). In these subgroups, respectively, AEs led to treatment discontinu

SUBMITTER: Volkmann ER 

PROVIDER: S-EPMC10749375 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature